NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-05-04 |
2022-03 |
-0.46 |
N/A |
N/A |
N/A |
2022-03-14 |
2021-12 |
-0.31 |
N/A |
N/A |
N/A |
2021-11-10 |
2021-09 |
-0.29 |
N/A |
N/A |
N/A |
2021-08-11 |
2021-06 |
-0.28 |
N/A |
N/A |
N/A |
2021-05-05 |
2021-03 |
-0.29 |
N/A |
N/A |
N/A |
2021-04-05 |
2020-12 |
-0.37 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2021-03-03 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2020-10-14 |
B. Riley FBR |
Upgrade |
|
Buy |
2020-02-06 |
Maxim Group |
Upgrade |
|
Buy |
2019-07-30 |
Brookline Capital |
Upgrade |
|
Buy |
2018-06-26 |
H.C. Wainwright |
Upgrade |
|
Buy |
2016-06-20 |
Roth Capital |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2018-12-31 |
HUTCHINS JEFF TOBIN PH.D. |
Officer |
143.14K |
Stock Award(Grant) |
2020-08-12 |
OSTRANDER WILLIAM L. |
Officer |
11.19K |
Conversion of Exercise of derivative security |
2020-01-01 |
PRENDERGAST JOHN K. A. PH.D. |
Director |
700.00K |
Stock Award(Grant) |
2018-12-31 |
ROSAR ANN A |
Officer |
93.38K |
Stock Award(Grant) |
2020-11-11 |
SMITH EDWARD B III |
Director |
0.00 |
Sale |
2020-01-01 |
WOLF JEFFREY ALAN J.D. |
Chief Executive Officer |
3.94M |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
Vanguard Group, Inc. (The) |
1.10M |
3.36M |
4.32% |
2022-03-30 |
Blackrock Inc. |
471.91K |
1.44M |
1.86% |
2022-03-30 |
Geode Capital Management, LLC |
249.54K |
763.59K |
0.98% |
2022-03-30 |
LPL Financial LLC |
133.05K |
407.15K |
0.52% |
2022-03-30 |
State Street Corporation |
102.98K |
315.13K |
0.41% |
2022-03-30 |
Morgan Stanley |
75.94K |
232.36K |
0.30% |
Report Date |
Organization |
Position |
Value |
Percentage |
2021-12-30 |
Vanguard Total Stock Market Index Fund |
705.53K |
2.14M |
2.78% |
2021-12-30 |
Vanguard Extended Market Index Fund |
353.50K |
1.07M |
1.39% |
2022-02-27 |
Fidelity Extended Market Index Fund |
159.44K |
414.54K |
0.63% |
2022-01-30 |
iShares Micro Cap ETF |
60.31K |
176.11K |
0.24% |
2022-02-27 |
IndexIQ ETF Tr-IQ Chaikin U.S. Small Cap ETF |
57.97K |
150.71K |
0.23% |
2022-01-30 |
DFA U.S. Small Cap Series |
41.17K |
120.20K |
0.16% |
Split |
Date |
1 : 7 |
2020-12-11 |
1 : 10 |
2018-01-22 |